Canadian Cardiovascular Society Clinical Practice Update on Contemporary Management of the Patient With Hypertrophic

Andrew M Crean1, Arnon Adler2, Laura Arbour3

  • 1Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada; North West Heart Center, Manchester, United Kingdom.

Insights

This clinical practice update offers practical guidance on hypertrophic cardiomyopathy (HCM) care for general cardiologists. It distills expert experience for effective diagnosis, treatment, and risk assessment in HCM patients, including pediatric considerations.

Area of Science:

  • Cardiology
  • Clinical Practice Guidelines
  • Cardiovascular Medicine

Background:

  • Numerous hypertrophic cardiomyopathy (HCM) guidelines exist but are often lengthy and less accessible to non-specialists.
  • This document synthesizes practical experience and peer-reviewed literature for effective HCM management.
  • It targets general cardiologists and cardiovascular practitioners, not solely HCM specialists.

Purpose of the Study:

  • To provide a concise, experience-based concentrate on essential hypertrophic cardiomyopathy (HCM) care.
  • To distill the essence of effective and appropriate HCM management for a broader clinical audience.
  • To offer practical insights beyond traditional, lengthy guidelines.

Main Methods:

  • Expert consensus opinion derived from extensive practical experience and literature review.
  • Focus on key aspects of HCM: diagnosis, obstruction identification, imaging, genetic testing, and therapeutics.
  • Inclusion of pediatric considerations and sudden cardiac death risk assessment.

Main Results:

  • Comprehensive overview of hypertrophic cardiomyopathy (HCM) clinical presentation and diagnosis.
  • Emphasis on identifying and managing obstruction in HCM.
  • Review of cardiac magnetic resonance imaging, genetic testing, and treatment options, including cardiac myosin inhibitors.

Conclusions:

  • This update provides practical, experience-driven insights for managing hypertrophic cardiomyopathy (HCM).
  • It covers essential elements from diagnosis to end-stage care, including pediatric nuances.
  • Emphasizes expert judgment over dogma in individual patient management.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
632
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420